hepatocellular carcinoma
Conditions
Interventions
B-TACE with porous gelatin particles
B-TACE with microspheres
Sponsors
Gastroenterology & Hepatology, Faculty of Medicine, Saitama Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Histologically or clinically diagnosed hepatocellular carcinoma 2)Unresectable hepatocellular carcinoma 3)No indication for radiofrequency ablation 4)Cure is impossible by radiofrequency ablation alone 5)Child-Pugh class A or B 6)Maximum tumor diameter less than or equal to 6 cm 7)No portal vein thrombosis, A-V shunt or A-P shunt 8)Adequate organ funcion 1. WBC >= 2000 /mm3 2. PLT >= 20000 /mm3 3. Hb >= 8.0 g /dl 4. Cr < 1.2 mg /dl 5. BUN <= 25 mg /dl 6. PT >= 50% 7. T-bil < 3.0 mg /dl 9)Patients who are considered to be appropriate to recieve TACE by their physicians
Exclusion criteria
Exclusion criteria: 1)Previous history of TACE 2)Severe concomitant disease (excluding chronic liver disease) 3)Receiving sorafenib 4)Developed esophagogastric varices 5)History of severe allergy to platinum complex or iodine contrast material 6)Pregnant or lactating female 7)Patients who are considered to be inappropriate to participate in this study by their physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Therapeutic effect | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety | — |
Countries
Japan
Contacts
Public ContactYukinori Imai
Saitama Medical University Gastroenterology & Hepatology, Faculty of Medicine
Outcome results
None listed